Lv3
218 积分 2025-06-05 加入
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
25天前
已关闭
Active Monitoring, Surgery, and Radiotherapy for Cribriform-Positive and Cribriform-Negative Prostate Cancer
1个月前
已完结
Cribriform-Positive and -Negative Prostate Cancer
1个月前
已关闭
Radiotheranostic landscape: A review of clinical and preclinical development
4个月前
已完结
Glypican-3-Targeted PET Imaging for Precise Diagnosis of Hepatocellular Carcinoma: From Bench to Bedside
4个月前
已完结
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy
4个月前
已完结
Detection of Peritoneal Lesions of Hepatocellular Carcinoma Using [
4个月前
已关闭
Biodistribution and Radiation Dosimetry of [ 68 Ga]Ga-RAYZ-8009, a Glypican 3–Targeting Compound for Imaging of Hepatocellular Carcinoma
4个月前
已完结
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
4个月前
已完结
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial
4个月前
已完结
皖公网安备34019202002308
